vTv Therapeutics (VTVT) to Release Quarterly Earnings on Monday

vTv Therapeutics (NASDAQ:VTVT) is expected to be announcing its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.87) per share for the quarter.

vTv Therapeutics Price Performance

VTVT stock opened at $14.85 on Friday. The company has a market cap of $47.37 million, a P/E ratio of -3.28 and a beta of 1.07. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $30.99. The firm has a 50-day moving average of $16.47 and a 200 day moving average of $15.31.

Analyst Ratings Changes

A number of research firms have recently commented on VTVT. Alliance Global Partners began coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price target on the stock. StockNews.com started coverage on shares of vTv Therapeutics in a research report on Tuesday, March 11th. They set a “sell” rating on the stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.